Floatz logo

JAB 3068

Non-small Cell Lung Cancer

Jacobio Pharmaceuticals Co., Ltd.Small moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
59/ 100

Competitive context

1206 Active assets in the Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

JAB 3068 is also rated in:

metastatic neoplasmDormant
B
Indicative ·
60 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
55 / 100
View asset →
esophageal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →